Business · 16/11/2017
FDA Releases Draft Guidance on Biosimilar User Fee Amendments of 2017
The FDA is announcing the availability of a draft guidance for industry regarding the implementation of the Biosimilar User Fee Amendments of 2017 and changes to policies and procedures surrounding its application.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →